<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02065154</url>
  </required_header>
  <id_info>
    <org_study_id>UAB 1286</org_study_id>
    <nct_id>NCT02065154</nct_id>
  </id_info>
  <brief_title>Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis</brief_title>
  <official_title>Phase II Clinical Trial of the Use of Post-Transplant Cyclophosphamide for Graft Versus Host Disease (GvHD) Prophylaxis Following Matched Unrelated Donor (MUD) and Mismatched Unrelated Donor (MMUD)Hematopoietic Stem Cell Transplant (HSCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to assess the effects of cyclophosphamide (cytoxan) in the
      post transplant setting to prevent onset of acute graft-versus-host disease (GVHD). The
      primary objective is to determine the incidence of grade II-IV acute GVHD following
      Allogeneic (allo) Hematopoeitic Cell Transplant (HCT) using post-transplant cyclophosphamide
      (cytoxan) for patients with human leukocyte antigen (HLA) matched unrelated (MUD) and
      mismatched unrelated (MMUD) donors. Other objectives for this study will be the determination
      of disease-free survival (DFS) and overall survival (OS) following allo HCT and assess the
      safety of post-transplant cyclophosphamide (cytoxan) for MUD and MMUD transplantation.
      Disease recurrence and time to recurrence in patients receiving post-transplant
      cyclophosphamide compared to historical control without post-transplant cyclophosphamide
      (cytoxan) will also be evaluated. Other objectives will be to determine the time of onset,
      severity, responsiveness to treatment, organs involved of acute and chronic GVHD as well as
      observation of Immune Reconstitution over time.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Grade II-IV acute GVHD</measure>
    <time_frame>Assessed 1 time per week until 100 days post transplant. Then assessed 1 time per month until 1 year post transplant.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1 Year Post Transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival</measure>
    <time_frame>1 Year Post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regimen Related Toxicity</measure>
    <time_frame>100 Days Post Transplant</time_frame>
    <description>Regimen Related Toxicity will be assessed for incidence within the first 100 days of transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Reconstitution</measure>
    <time_frame>Days +30, +100, +18-, +365. And as clinically indicated.</time_frame>
    <description>The rate and pattern of recovery of total lymphocytes, T cell subsets, B cells, and NK calls are evaluated by flow cytometry and are quantified and reported as percentages of total cell counts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse Rate</measure>
    <time_frame>2 years post-transplant</time_frame>
    <description>Relapse rate will be assessed at 2 years post-transplant</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Myelofibrosis</condition>
  <condition>Severe Aplastic Anemia</condition>
  <condition>Allogeneic Transplant</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclophosphamide (Cytoxan)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Disease Criteria: patients must meet diagnostic criteria of acute myeloid leukemia
             (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), chronic
             lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL),
             myelodysplastic syndrome (MDS), myelofibrosis, or severe aplastic anemia. Patients
             will be allowed on study if they are deemed eligible for allo HCT regardless of
             remission status.

          -  Age Criteria: 19 to 65 years in age.

          -  Organ Function Criteria: All organ function testing should be done within 28 days of
             study registration.

          -  Cardiac: Left ventricular ejection fraction (LVEF) ≥ 50% by MUGA (Multi Gated
             Acquisition) scan or echocardiogram.

          -  Pulmonary: FEV1 (Forced expiratory volume in 1 second) and FVC (Forced vital capacity)
             ≥ 50% predicted, DLCO (diffusing capacity of the lung for carbon monoxide) (corrected
             for hemoglobin) ≥ 50% of predicted.

          -  Renal: The estimated creatinine clearance (CrCl) must be equal or greater than 60
             mL/min/1.73 m2 as calculated by the Cockcroft-Gault Formula:

        CrCl=(140-age) x weight(kg) x 0.85 (if female)/72 x serum creatinine (mg/dL)

          -  Hepatic:

               -  Serum bilirubin 1.5 upper limit of normal (ULN)

               -  Aspartate transaminase (AST)/alanine transaminase (ALT) 2.5 ULN

               -  Alkaline phosphatase 2.5 ULN

          -  Performance status: Karnofsky ≥ 70%.,

          -  Patient must be informed of the investigational nature of this study in accordance
             with institutional and federal guidelines and have the ability to provide written
             informed consent prior to initiation of any study-related procedures, and ability, in
             the opinion of the principal investigator, to comply with all the requirements of the
             study.

          -  Patient has a suitable and willing HLA-8/8 matched or 6/8 mismatched (at one allele)
             unrelated donor identified.

        Exclusion Criteria:

          -  Non-compliant to medications.

          -  No appropriate caregivers identified.

          -  HIV1 (Human Immunodeficiency Virus-1) or HIV2 positive

          -  Uncontrolled medical or psychiatric disorders.

          -  Uncontrolled infections, defined as positive blood cultures within 72 hours of study
             entry, or evidence of progressive infection by imaging studies such as chest CT scan
             within 14 days of registration.

          -  Active central nervous system (CNS) leukemia.

          -  Preceding allogeneic HSCT.

          -  Pregnancy or Breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Racquel D Innis-Shelton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tiffany Hill, RN</last_name>
    <phone>205-996-8023</phone>
    <email>tiffanydhill@uabmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UAB Bone Marrow Transplantation and Cellular Therapy Program</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany D Hill, RN</last_name>
      <phone>205-996-8023</phone>
      <email>tiffanydhill@uabmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lindsey M Stephens, RN</last_name>
      <phone>205-975-2713</phone>
      <email>lmeggs@uabmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Racquel D Innis-Shelton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ayman A Saad, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Donna Salzman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ruby F Meredith, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lawrence S Lamb, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Di Stasi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luciano Costa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.uab.edu/medicine/bonemarrow/</url>
    <description>UAB Bone Marrow Transplantation and Cell Therapy Program</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2013</study_first_submitted>
  <study_first_submitted_qc>February 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2014</study_first_posted>
  <last_update_submitted>October 29, 2017</last_update_submitted>
  <last_update_submitted_qc>October 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Racquel Innis-Shelton, MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>acute myeloid leukemia</keyword>
  <keyword>AML</keyword>
  <keyword>acute lymphoblastic leukemia</keyword>
  <keyword>ALL</keyword>
  <keyword>chronic myeloid leukemia</keyword>
  <keyword>CML</keyword>
  <keyword>chronic lymphocytic leukemia</keyword>
  <keyword>CLL</keyword>
  <keyword>non-Hodgkin lymphoma</keyword>
  <keyword>NHL</keyword>
  <keyword>Hodgkin lymphoma</keyword>
  <keyword>HL</keyword>
  <keyword>myelodysplastic syndrome</keyword>
  <keyword>MDS</keyword>
  <keyword>myelofibrosis</keyword>
  <keyword>severe aplastic anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

